Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05871541 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine
A Phase 1 study of Infectious Disease and Shingles, sponsored by Immorna Biotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
- 3
- Study locations
NCT05871541 is a Phase 1 study of Infectious Disease and Shingles that has completed, run by Immorna Biotherapeutics. The registered enrollment target is 75 participants, below the 7,021-participant average among 18 other Infectious Disease trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT05871541, a Phase 1 study of Infectious Disease and Shingles, has completed, sponsored by Immorna Biotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this clinical trial is to assess the safety and immunogenicity of a self-replicating (sr) RNA-based vaccine, JCXH-105, in the prevention of Shingles (Herpes Zoster) Participant will be randomized to receive either JCXH-105 or Shingrix.
Conditions Studied
Interventions
- BIOLOGICAL JCXH-105
- BIOLOGICAL Active Control (Shingrix)
Study Locations (3)
Florida
- CenExel RCA - Hollywood
- CenExel FCR - Tampa
New Jersey
- CenExel HRI - Berlin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2023-05-26 |
| Est. Completion | 2024-03-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05871541
The ClinicalTrials.gov registry entry for NCT05871541 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 7,021-participant average among 18 other Infectious Disease trials with a reported enrollment target (99% lower). The listed sponsor is Immorna Biotherapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Infectious Disease appearing as the primary indexed condition, and to 2 interventions - of which JCXH-105 is the first listed.
NCT05871541 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Florida, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05871541 about?
NCT05871541 is a clinical study titled "A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine". The goal of this clinical trial is to assess the safety and immunogenicity of a self-replicating (sr) RNA-based vaccine, JCXH-105, in the prevention of Shingles (Herpes Zoster) Participant will be randomized to receive either JCXH-105 or Shingrix.
What is the current status of trial NCT05871541?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2023-05-26. Estimated completion is 2024-03-25.
What conditions does trial NCT05871541 study?
This clinical trial studies the following conditions: Infectious Disease, Shingles, Herpes Zoster (HZ).
What interventions are being tested in trial NCT05871541?
The interventions under investigation include: JCXH-105 (BIOLOGICAL), Active Control (Shingrix) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05871541?
This trial is sponsored by Immorna Biotherapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05871541 being conducted?
This trial has 3 study locations across Florida, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infectious Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV
ACTIVE NOT RECRUITING · Phase 1
-
Compliant Analysis of Patient Samples and Data
RECRUITING
-
Collection and Distribution of Biospecimens for Novel Research Uses
RECRUITING
-
Ocular Pathogen and Transcriptome Investigation Using Comprehensive Sequencing
RECRUITING · NA
-
Triage Survey for Infectious Disease Eligibility
RECRUITING
-
Antibiotics for Delirium in Older Adults With No Clear Urinary Tract Infection
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.